PEGCETACOPLAN (APL-2)
APL2-GA-305
Phase 3 small_molecule completed
Quick answer
PEGCETACOPLAN (APL-2) for Geographic Atrophy Secondary to Age-related Macular Degeneration is a Phase 3 program (small_molecule) at Apellis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Apellis Pharmaceuticals
- Indication
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed